BeOne Medicines Ltd. ONC revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BeOne Medicines Ltd. reported revenue across 2 products and services; the largest, Product, was $5.28B, 98.9% of the filed sum (+39.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$5.28B98.9%+39.8% yoy
- Collaboration$61M1.1%+98.6% yoy
Members sum to the consolidated $5.34B for this period.
- United States$2.88B53.9%+47.1% yoy
- China$1.68B31.4%+19.0% yoy
- Europe$611M11.4%+68.6% yoy
- All Other Countries Except China United States Of America And Switzerland$172M3.2%+118.0% yoy
Members sum to the consolidated $5.34B for this period.
- Product$1.49B98.3%+34.2% yoy
- Other Revenue$26.1M1.7%+198.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.